These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23494862)

  • 1. A drug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release.
    You JO; Guo P; Auguste DT
    Angew Chem Int Ed Engl; 2013 Apr; 52(15):4141-6. PubMed ID: 23494862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells.
    Sharma AK; Sharma R; Chauhan N; Das A; Satpati D
    J Pept Sci; 2024 Sep; 30(9):e3602. PubMed ID: 38600778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
    Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies.
    Helmi O; Elshishiny F; Mamdouh W
    Int J Biol Macromol; 2021 Aug; 184():325-338. PubMed ID: 34119547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable ZnO@polymer core-shell nanocarriers: pH-triggered release of doxorubicin in vitro.
    Zhang ZY; Xu YD; Ma YY; Qiu LL; Wang Y; Kong JL; Xiong HM
    Angew Chem Int Ed Engl; 2013 Apr; 52(15):4127-31. PubMed ID: 23463695
    [No Abstract]   [Full Text] [Related]  

  • 7. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
    Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
    Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo.
    Wang X; Sun Q; Cui C; Li J; Wang Y
    Drug Des Devel Ther; 2018; 12():2841-2855. PubMed ID: 30233146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic Multilayer Capsules for Ultrasound Imaging and Guided Drug Delivery.
    Chen J; Ratnayaka S; Alford A; Kozlovskaya V; Liu F; Xue B; Hoyt K; Kharlampieva E
    ACS Nano; 2017 Mar; 11(3):3135-3146. PubMed ID: 28263564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
    Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
    Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
    J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
    Naruphontjirakul P; Viravaidya-Pasuwat K
    Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes.
    Shi M; Zhang J; Li X; Pan S; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
    Int J Nanomedicine; 2018; 13():4209-4226. PubMed ID: 30140154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
    Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
    Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
    Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
    Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
    Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
    Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
    Lale SV; R G A; Aravind A; Kumar DS; Koul V
    Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
    Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
    J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.
    Zhang C; Han M; Zhang F; Yang X; Du J; Zhang H; Li W; Chen S
    Int J Nanomedicine; 2020; 15():885-900. PubMed ID: 32103944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multi-action Pt
    Kostrhunova H; Zajac J; Markova L; Brabec V; Kasparkova J
    Angew Chem Int Ed Engl; 2020 Nov; 59(47):21157-21162. PubMed ID: 32750194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.